



**ALLOCATION LIST (CONDENSED) OF AVAILABLE CLINICAL TRIALS AT ALTRU=7/17/2020**

**BREAST**

ADJUVANT Node+, HER2-, any ERPR status allowed	<u>A011502</u>
RADIOTHERAPY IN BIOMARKER LOW RISK NODE + BREAST CA	<u>MA.39</u>
ADJUVANT Node+ or High-Risk Node- TNBC	<u>NRG-BR003</u>
TREATMENT AFTER NEOADJ CHEMO IN TNBC-RESIDUAL DISEASE	<u>EA1131</u>

**CNS**

NEWLY DIAGNOSED ANAPLASTIC GLIOMA	<u>NCCTG N0577</u>
-----------------------------------	--------------------

**LUNG**

LIMITED STAGE SCLC	<u>NRG-LU005</u>
LS- OR EX-SCLC: MRI SURVEILLANCE w or w/o PCI	<u>S1827</u>

**Cancer Control/Symptom Management**

<b>ADJUVANT</b> Hypofractionated post-Mastectomy Rx with Breast Reconstruction	<u>A221505</u>
<b>PREVENTION</b> Olanzapine with or without Fosaprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)	<u>A221602</u>